Article ; Online: Beta 2 Adrenergic Receptor Genetic Polymorphisms in Bronchial Asthma: Relationship to Disease Risk, Severity, and Treatment Response.
2018 Volume 196, Issue 6, Page(s) 673–680
Abstract: Background: The β: Objective: The purpose of the study was to determine the association between β: Subjects and methods: 58 asthmatic patients and 38 healthy subjects were included. The β: Results: The allelic frequencies for the Arg16Gly ... ...
| Abstract | Background: The β Objective: The purpose of the study was to determine the association between β Subjects and methods: 58 asthmatic patients and 38 healthy subjects were included. The β Results: The allelic frequencies for the Arg16Gly polymorphism were 15.5%, 48.3%, and 36.2% for the homozygous A wild, heterozygous, and homozygous G mutant alleles in asthmatics (P < 0.01) and 5.3%, 47.4%, and 47.4% in healthy subjects (P < 0.01). For the Gln27Glu polymorphism, the allelic frequencies for the homozygous C wild, heterozygous and homozygous G mutant alleles were 51.7%, 41.4%, and 6.9% in asthmatics (P < 0.01) and 44.7%, 39.5%, and 15.8% in healthy subjects (P < 0.01). The heterozygous Arg16Gly and Gln27Glu were found in most of severe asthma cases (7/13, 53.8% each). While homozygous wild and mutant seemed to be protective and associated with mild disease in both alleles. Finally, 75% of Arg16Gly heterozygous group were good responders (P < 0.01), 81% of homozygous G mutant were bad responders. For Gln27Glu polymorphism, 60% of C wild group were good responders and 75% of G mutant group were bad responders. Conclusions: The findings suggest that the Arg16Gly and Gln27Glu polymorphisms in the β2-AR gene are associated with asthma severity and response to therapy and might be used in personalized treatment for these patients in the future. This work is registered in ClinicalTrial.gov with ID: NCT03118869. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Adolescent ; Adult ; Asthma/drug therapy ; Asthma/genetics ; Case-Control Studies ; Female ; Gene Frequency ; Heterozygote ; Homozygote ; Humans ; Male ; Middle Aged ; Polymorphism, Single Nucleotide ; Receptors, Adrenergic, beta-2/genetics ; Risk Factors ; Severity of Illness Index ; Treatment Outcome ; Young Adult | |||||
| Chemical Substances | Receptors, Adrenergic, beta-2 | |||||
| Language | English | |||||
| Publishing date | 2018-09-03 | |||||
| Publishing country | United States | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 6165-7 | |||||
| ISSN | 1432-1750 ; 0341-2040 | |||||
| ISSN (online) | 1432-1750 | |||||
| ISSN | 0341-2040 | |||||
| DOI | 10.1007/s00408-018-0153-3 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Uh II Zs.20: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.